FY2028 Earnings Forecast for Disc Medicine Issued By Wedbush

Disc Medicine, Inc. (NASDAQ:IRON) – Research analysts at Wedbush increased their FY2028 EPS estimates for shares of Disc Medicine in a report issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now expects that the company will post earnings per share of $7.04 for the year, up from their prior estimate of $6.85. Wedbush currently has a “Outperform” rating and a $83.00 target price on the stock. The consensus estimate for Disc Medicine’s current full-year earnings is ($4.15) per share.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Tuesday, November 12th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.15.

Other research analysts have also recently issued reports about the stock. Scotiabank boosted their target price on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 5th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $85.00 price target on shares of Disc Medicine in a report on Tuesday, October 15th. Morgan Stanley upgraded shares of Disc Medicine from an “equal weight” rating to an “overweight” rating and set a $85.00 price objective on the stock in a research note on Tuesday, November 5th. Raymond James upgraded Disc Medicine from an “outperform” rating to a “strong-buy” rating and raised their target price for the company from $66.00 to $110.00 in a research note on Monday, November 4th. Finally, Jefferies Financial Group began coverage on Disc Medicine in a research report on Wednesday, October 23rd. They set a “buy” rating and a $89.00 price objective for the company. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Disc Medicine has a consensus rating of “Buy” and an average price target of $85.80.

Disc Medicine Stock Performance

IRON opened at $59.46 on Thursday. The company has a market cap of $1.77 billion, a PE ratio of -14.94 and a beta of 0.60. Disc Medicine has a 1 year low of $25.60 and a 1 year high of $77.60. The firm has a 50 day moving average price of $51.20 and a 200 day moving average price of $44.97.

Hedge Funds Weigh In On Disc Medicine

Several institutional investors have recently modified their holdings of the stock. Amalgamated Bank increased its holdings in shares of Disc Medicine by 76.9% in the second quarter. Amalgamated Bank now owns 568 shares of the company’s stock worth $26,000 after acquiring an additional 247 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in Disc Medicine by 45.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company’s stock worth $54,000 after acquiring an additional 337 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in Disc Medicine by 2.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 29,065 shares of the company’s stock valued at $1,428,000 after purchasing an additional 771 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Disc Medicine by 19.5% during the 3rd quarter. SG Americas Securities LLC now owns 4,864 shares of the company’s stock worth $239,000 after acquiring an additional 793 shares during the period. Finally, Bleakley Financial Group LLC increased its holdings in shares of Disc Medicine by 23.0% in the first quarter. Bleakley Financial Group LLC now owns 4,572 shares of the company’s stock valued at $285,000 after purchasing an additional 856 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Disc Medicine

In related news, Director William Richard White sold 7,136 shares of Disc Medicine stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $58.61, for a total value of $418,240.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 7,538 shares of company stock valued at $437,875 in the last 90 days. 4.24% of the stock is currently owned by company insiders.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.